Despite the success of immunotherapy, it is still limited due to the poor control of which T cells are activated and how strong and how long they are activated. Next-generation T-cell activators should address this limitation by engagement of selective T-cell subsets, allowing stronger control and durable responses. Ipsen SA has presented data regarding their T-cell activator IPN-01203, which is bispecific and selective for Vβ6 and Vβ10 (Vβ6/10) TCR-expressing T cells, alongside with IL-15 receptor coactivation.
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on machine learning has identified DNA-methylation patterns that reveal the type of tissue a cancer comes from when the primary tumor cannot be found. This technique could help guide more specific treatments for patients with cancers of unknown primary, who today often receive broad, nontargeted chemotherapy.
Tango Therapeutics Inc. has synthesized substituted piperidine-dione molecular glue degraders comprising E3 ubiquitin ligase-binding moiety and acting as HBS1-like protein (HBS1L; HBS1) degradation inducers for use in the treatment of cancer.
Mindrank AI Co. Ltd. and Mindrank Therapeutics (Suzhou) New Drug Research have disclosed new Wee1-like protein kinase (Wee1) and/or tyrosine-protein kinase Yes (YES1) inhibitors potentially useful for the treatment of cancer, inflammation and autoimmune diseases.
Changchun Genescience Pharmaceuticals Co. Ltd. has reported new parathyroid hormone receptor 1 (PTHR1) agonists potentially useful for the treatment of arthritis, fracture, hyperphosphatemia and more.
Chinese researchers have published data regarding phosphatidylserine (PS) derivatives acting as neuroprotective compounds for Alzheimer’s disease (AD) therapy.
Researchers from Sanofi SA have detailed the development of a next-generation HER2-targeting T-cell engager (TCE) to increase selectivity for HER2-low tumor cells, while minimizing its effects on normal tissues expressing physiologic levels of HER2.
Although antibodies to PD-L1 are used in the clinic, their benefit is limited by immune exclusion within the local microenvironment. Objective response rates with anti-PD-L1 monotherapy are low due to the heterogeneity of PD-L1 expression, low tumor mutational burden and the highly immunosuppressive tumor microenvironment (TME) of cholangiocarcinoma (CCA).
RSS
